Rapid Response Revival’s inaugural Medical Research Advisory Board (L-R) Dr Adele Hosseini, Dr Barry Gunn, Prof Wendy Cross, Charles Johnson, Dr Chandana Unnithan, Brian Haskins
Medical Research Advisory Board appointed to Rapid Response Revival
[SYDNEY, AUSTRALIA] Thursday 19 January 2022: Privately-owned medical device start-up, Rapid Response Revival [RRR] has taken the next vital step in its journey to release the world’s first personal AED [automated external defibrillator], CellAED®.
RRR has attracted an impressive group of medical experts to its inaugural, formal Medical Research Advisory Board [MRAB]. Together, the Board represents expertise in the fields of emergency medicine, paramedicine, cardiovascular medicine, electrophysiology, neurology, data science, health informatics, regulatory affairs, clinical trials (methodology and GCP), novel medical devices and AEDs, health app development, biological health sciences, public health and human usability.
The formalisation of its MRAB is a vital next step for the Sydney-based company which, since before its incorporation in 2017, has drawn heavily on external medical expertise in the development of its ground-breaking CellAED® personal defibrillator.
CellAED®, which currently has regulatory approval to supply to more than 75 countries and territories around the world, was developed to make defibrillation more accessible in the homes of people at risk of sudden cardiac arrest.
“We have developed a ground-breaking, life-saving device which has revolutionised AED technology,” said RRR founder and CEO, Donovan Casey.
“Since 2017, every step of the way, we have consulted with thousands of emergency first-responders, electro-cardiologists, first aid trainers, those in the field of innovative tech and other experts worldwide. The formation of this Medical Research Advisory Board is an important next phase for us.
“We are gratified that people of the very highest calibre in their fields have committed to sharing their expertise with us. They have all expressed a desire to be part of the exciting and radical change CellAED® represents, and play a role in improving the chances of surviving out-of-hospital cardiac arrest.”
The MRAB’s role will be to guide current and future research and development, and help shape the social proofing of RRR technology and solutions, beginning with CellAED®.
“This Board is here to make sure we remain rooted in the real problems that need solving, and that what we create delivers those solutions.
“While they come from different backgrounds and fields of medical science, each member of this team is here for the same reason. They want to find better ways to save more of the seven to nine million people who die from sudden cardiac arrest every year.
“They know that around 80 per cent of these people die at home. They share our commitment to making defibrillation available to these people, where it’s needed, so they can be helped in those critical first minutes following a cardiac arrest,” Mr Casey said.
Joining the Rapid Response Revival Medical Research Advisory Board are, in alphabetical order:
Professor Wendy M. Cross – Dean of the School of Health, Federation University Australia. Wendy brings four decades’ experience as a clinician, academic and applied research Principal Investigator, focused on nursing and various related aspects of clinical health care.
Dr Barry Gunn – Specialist Emergency Physician, Western Health Australia. Barry brings more than 30 years of emergency medicine experience to the MRAB, including expertise as both a practising Emergency Physician and an educator. Barry’s experience has made him acutely aware of the barriers to surviving out-of-hospital cardiac arrest, and the need for better solutions to those problems.
Brian Haskins – Director of Pre-Hospital Trauma Life Support, Monash University. A 30-year veteran of paramedicine, Brian is one of the world’s leading authorities on the role of bystander response to improving the chances of surviving out-of-hospital cardiac arrest.
Dr Adele Hosseini – Chief Scientific Officer, Bod Australia. Adele is a PhD pharmacist with more than 30 years’ experience in global clinical research and regulatory affairs in fields including pharmaceuticals, medical devices and academia. Adele is internationally recognised as a leader in shaping the scientific function of innovation biotech.
Charles Johnson – Emergency and Flight Physician, and Medical Director, Hope Medical Services Singapore. Charles is a Fellow of the Royal Society of Edinburgh and founder of Hope, which delivers basic- and advanced life support care on land, air and sea in South-East Asia. As an experienced first responder, Charles plays an active role in efforts to promote CPR training and AED access to all, wherever it is needed.
Dr Chandana Unnithan – Chief Security and Informatics Office (CSIO), Lifeguard Digital Health Canada. An expert scientist in digital health, Chandana is a pioneer in innovative technological health solutions incorporating artificial intelligence, IoT, blockchain and telehealth. Author of more than 140 scientific papers, Chandana has held advisory positions with the World Health Organisation and the United Nations.
Rapid Response Revival co-founder and CEO, Donovan Casey is available for interview on request
About Rapid Response Revival
Rapid Response Revival is a privately-owned Sydney, Australia-based start-up medical technology Company, established in 2017. Its mission is tackling the unacceptably low survival rate of out-of-hospital cardiac arrest.
RRR was established by Donovan Casey, after his partner Sarah experienced a sudden cardiac arrest in their home. Sarah survived, unlike most people who experience out-of-hospital cardiac arrest.
RRR’s marquee product is CellAED®, designed to make AEDs easier to use, easier to carry, and more affordable. CellAED® represents the first real improvements on AED technology in more than 30 years, and is the world’s first personal AED.
RRR is the Company that designed, patented and will manufacture and deliver CellAED® to the world. CellAED® is currently approved for supply to more than 75 countries and territories around the world, including the European Economic Area member countries, and Australia.